Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Rush University Cancer Center

1 abstract

Abstract
A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).
Org: Rush University Cancer Center, Ideker Laboratory, Alliance Foundation Trials,